TP53 mutations in clinically normal mucosa adjacent to oral carcinomas

Journal of Oral Pathology and Medicine

Volumn 39, Issue 9, 2010, Pages 662-666

  Thode, C ^a   Bilde, A ^b   Von Buchwald, C ^b   Dabelsteen, E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

microdissection; oral cancer; p53; resection margins

Indexed keywords

DNA; PHOSPHORUS 32; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; DENATURING GRADIENT GEL ELECTROPHORESIS; EXON; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LASER CAPTURE MICRODISSECTION; MOUTH CARCINOMA; MOUTH MUCOSA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA MUTATIONAL ANALYSIS; EPITHELIAL CELLS; HUMANS; MICRODISSECTION; MOUTH MUCOSA; MOUTH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77957585631     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00916.x     Document Type: Article

References (34)

1. Slootweg PJ, Hordijk GJ, Schade Y, van Es RJ, Koole R. Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol 2002 38 : 500 503.
2. Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984 53 : 563 568.
3. Holmstrup P. Can we prevent malignancy by treating premalignant lesions? Oral Oncol 2009 45 : 549 550.
4. Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000 6 : 347 352.
5. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003 63 : 1727 1730.
6. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000 29 : 413 425.
7. el-Naggar AK, Lai S, Luna MA, et al. Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 1995 64 : 196 201.
8. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995 10 : 1217 1227.
9. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, el-Naggar AK. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002 33 : 158 164.
10. Huang X, Pateromichelakis S, Hills A, et al. p53 mutations in deep tissues are more strongly associated with recurrence than mutation-positive mucosal margins. Clin Cancer Res 2007 13 : 6099 6106.
11. Bennett WP, Hollstein MC, Hsu IC, et al. Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest 1992 101 (3 Suppl 19S 20S.
12. Cruz IB, Snijders PJ, Meijer CJ, et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998 184 : 360 368.
13. Bilde A, von BC, Dabelsteen E, Therkildsen MH, Dabelsteen S. Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med 2009 38 : 72 8.
14. Tabor MP, Brakenhoff RH, van Houten VM, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001 7 : 1523 1532.
15. van Houten VM, Tabor MP, van den Brekel MW, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 2002 198 : 476 486.
16. Partridge M, Costea DE, Huang X. The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg 2007 36 : 1123 1138.
17. Johnson GD. Quantitation in immunofluorescence by radioimmunoassay. Ann NY Acad Sci 1971 177 : 434 438.
18. McCluggage WG, Connolly LE, McGregor G, Hyland PL, Hall PA. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 2005 24 : 307 312.
19. Dabelsteen E. Quantitative determination of blood group substances A of oral epithelial cells by immunofluorescence and immunoperoxidase methods. Acta Pathol Microbiol Scand A 1972 80 : 847 853.
20. Mackenzie IC. Retroviral transduction of murine epidermal stem cells demonstrates clonal units of epidermal structure. J Invest Dermatol 1997 109 : 377 383.
21. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997 9 : 348 355.
22. Sheffield VC, Cox DR, Lerman LS, Myers RM. Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci USA 1989 86 : 232 236.
23. Dahl C, Ralfkiaer U, Guldberg P. Methods for detection of subtle mutations in cancer genomes. Crit Rev Oncog 2006 12 : 41 74.
24. Guldberg P, Gronbak K, Aggerholm A, et al. Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. Nucleic Acids Res 1998 26 : 1548 1549.
25. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 2007 36 : 262 266.
26. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990 250 : 1233 1238.
27. Tabori U, Malkin D. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008 68 : 2053 2057.
28. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994 54 : 4855 4878.
29. Tudor D, Locke M, Owen-Jones E, Mackenzie IC. Intrinsic patterns of behavior of epithelial stem cells. J Investig Dermatol Symp Proc 2004 9 : 208 214.
30. Ambler CA, Maatta A. Epidermal stem cells: location, potential and contribution to cancer. J Pathol 2009 217 : 206 216.
31. Farshadpour F, Hordijk GJ, Koole R, Slootweg PJ. Head and neck squamous cell carcinoma in non-smoking and non-drinking patients with multiple tumors: etiologic significance of p53 and Ki-67 in non-tumorous epithelium. J Oral Pathol Med 2008 37 : 549 554.
32. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer 2000 87 : 368 372.
33. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007 8 : 275 283.
34. Bartkova J, Gron B, Dabelsteen E, Bartek J. Cell-cycle regulatory proteins in human wound healing. Arch Oral Biol 2003 48 : 125 132.